Skip to content
OpenCapital
Get started

4D Molecular Therapeutics FDMT EV / sales

EV / sales at other companies

Eli Lilly logo
Eli LillyLLY
11.9×-4.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5.5×+0.6×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
9×-1.9×
EyePoint, Inc. logo
EyePoint, Inc. EYPT
134×+128×
AbbVie logo
AbbVieABBV
7.5×+1.0×
Regenxbio logo
RegenxbioRGNX
5.6×+3.6×

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
Enterprise value$550.27M+574%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Calculated from 4D Molecular Therapeutics’s reported figures.

enterprise value/total revenue=4.8×

Based on the most recent quarter.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's EV / sales?
4D Molecular Therapeutics (FDMT) reported EV / sales of 4.8× in Q1 2026.
How has 4D Molecular Therapeutics's EV / sales changed year-over-year?
4D Molecular Therapeutics's EV / sales decreased by 99.7% year-over-year, from 1,734.1× to 4.8×.
What is the long-term trend for 4D Molecular Therapeutics's EV / sales?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's EV / sales has grown at a -39.9% compound annual growth rate (CAGR), from 58.1× to 4.6×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.